May 8, 2025
Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran,...
Mar 14, 2024
Sibylla Biotech Enters a Strategic Drug Discovery Collaboration with Ono Pharmaceutical in Central Nervous System Disorders Milan, Italy, March 14, 2024 – Sibylla Biotech announced today a drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (TSE: 4528) that...
Oct 4, 2022
Sibylla Biotech Raises €23 Million Series A to Advance Protein Degradation by Folding Interference Pipeline and Expand Technology Platform Verona, Italy, October 4, 2022 – Sibylla Biotech today announced the successful close of its €23 million Series A financing round...
Jun 25, 2021
Sibylla Biotech selected by Nature among the eight best start-ups in the world in the life-science sector Sibylla Biotech, a spin-off of INFN, the University of Trento, and the University of Perugia, has been selected, the only Italian company, as a finalist of the...
May 22, 2021
Sibylla Biotech will use its Drug Discovery platform to modulate the activity of targets supplied by Takeda. The Italian startup company will partner its innovative PPI-FIT Drug Discovery platform with Takeda to generate novel compounds designed to modulate the...
Jan 22, 2021
The scientific paper about PPI-FIT technology and its first validation is now published on Nature Communications Biology! Spagnolli, G., Massignan, T., Astolfi, A. et l. Pharmacological inactivation of the prion protein by targeting a folding intermediate. Commun...
